ASMB Assembly Biosciences, Inc. - Fundamental Analysis
NEUTRAL
Sign in to save
Save this symbol to a watchlist or track a position.
ASMB Stock | Fundamental Analysis & Investment Insights
NASDAQ
Healthcare
Biotechnology
Current Price
Live
$29.84
Analyst Target
$47.75
+60.0%
Upside
52W High
$39.71
52W Low
$7.75
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Feb 28, 2026
Market cap
$471.98M
P/E
N/A
ROE
-36.9%
Profit margin
-103.6%
Debt/Equity
0.02
Dividend yield
N/A
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
72%
Analysis Accuracy
ASMB exhibits severe financial distress according to the Piotroski F-Score (0/9), indicating a weak financial health profile with no positive signals in profitability, leverage, or cash flow. The Altman Z-Score is unavailable, but the company's negative margins, deep losses, and high revenue volatility suggest elevated distress risk. Despite this, the stock shows strong revenue growth (57.6% YoY) and improving earnings surprises in recent quarters, supported by a 1Y return of +130.1%. Analysts maintain a bullish target price of $47.75, though consensus recommendations are absent. The valuation remains extremely stretched (Price/Sales: 12.69), reflecting high growth expectations rather than fundamental value.
Key Strengths
Strong revenue growth of 57.6% YoY, outpacing sector average
Improving earnings surprise trend in the last four quarters (average +12.52%)
Positive Q/Q EPS growth of +45.9% and YoY EPS growth of +52.3%
Low debt/equity ratio (0.02) and strong liquidity (Current Ratio: 4.44)
Insider sentiment at 40/100, indicating modest confidence despite losses
Key Risks
Piotroski F-Score of 0/9, signaling severe financial weakness and lack of operational stability
Negative profit margins across all metrics: -103.65% (Net), -100.87% (Operating), -66.29% (Gross)
No positive cash flow or earnings data; Free Cash Flow and Operating Cash Flow are unavailable
High valuation multiples (Price/Sales: 12.69) with no earnings to support them
No dividend, no Graham Number, and no intrinsic value estimate due to unprofitability and negative earnings
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
32
Weak
30
68
42
20
0
AI Verdict
Neutral
Key drivers: High revenue growth and improving earnings surprises, Severe financial distress per Piotroski F-Score, Unprofitable operations with negative margins, High valuation multiples without earnings support, Strong liquidity but no cash flow generation
Confidence
75%
Value
30/100
Ref P/E, PEG, Graham Number
Positives
- Revenue growth exceeds sector average
- Low debt/equity ratio (0.02)
Watchpoints
- No Graham Number or intrinsic value due to negative earnings
- Price/Sales of 12.69 is extremely high for a loss-making company
- Forward P/E of -8.52 indicates no earnings visibility
Future
68/100
Ref Growth rates
Positives
- 57.6% YoY revenue growth
- Improving earnings surprise trend (avg +12.52% over last 4 quarters)
- Q/Q EPS growth of +45.9%
Watchpoints
- No forward earnings guidance or positive earnings trajectory
- High growth expectations not yet reflected in profitability
Past
42/100
Ref Historical trends
Positives
- Consistent revenue growth over 25 quarters
- Improvement in earnings surprises from 2024 onward
Watchpoints
- Persistent losses with negative ROE (-36.94%) and ROA (-15.96%)
- Historical earnings volatility with large negative surprises
Health
20/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Very low debt/equity (0.02)
- High current and quick ratios (4.44, 4.39)
Watchpoints
- Piotroski F-Score of 0/9 indicates extreme financial weakness
- No positive signals in profitability, cash flow, or leverage
- No Altman Z-Score available, but distress risk is high due to losses and negative margins
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend yield or payout ratio
- Dividend Strength: 0/100
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$29.84
Analyst Target
$47.75
Upside/Downside
+60.0%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for ASMB and closest competitors.
Updated 2026-02-27
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
ASMB
Assembly Biosciences, Inc.
Primary
|
-50.8% | +82.8% | +130.1% | +20.8% | +12.9% | +3.8% |
|
BCYC
Bicycle Therapeutics plc
Peer
|
-74.2% | -74.7% | -47.5% | -20.1% | -0.6% | +6.8% |
|
AQST
Aquestive Therapeutics, Inc.
Peer
|
-27.7% | +432.4% | +47.8% | -20.4% | +5.2% | -4.7% |
|
ADCT
ADC Therapeutics SA
Peer
|
-89.4% | -22.9% | +105.1% | +10.1% | +2.3% | -0.3% |
|
ALT
Altimmune, Inc.
Peer
|
-80.3% | -68.4% | -32.7% | -3.9% | -24.4% | -1.1% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-8.52
PEG Ratio
N/A
P/B Ratio
2.58
P/S Ratio
12.69
EV/Revenue
6.51
EV/EBITDA
-5.59
Market Cap
$471.98M
Profitability
Profit margins and return metrics
Profit Margin
-103.65%
Operating Margin
-100.87%
Gross Margin
-66.29%
ROE
-36.94%
ROA
-15.96%
Growth
Revenue and earnings growth rates
Revenue Growth
+57.6%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.02
Low debt
Current Ratio
4.44
Strong
Quick Ratio
4.39
Excellent
Cash/Share
$14.7
Quarterly Earnings History
EPS performance vs analyst estimates
2025-11-10
$-0.72
-10.2% surprise
2025-08-06
$-1.33
+23.1% surprise
2025-05-08
$-1.17
+26.9% surprise
2025-03-20
$-1.57
+10.3% surprise
Healthcare Sector Comparison
Comparing ASMB against 147 companies in the Healthcare sector
(10 bullish, 55 neutral, 82 bearish)
Return on Equity (ROE)
-36.94%
This Stock
vs
-52.77%
Sector Avg
-30.0%
(Below Avg)
Profit Margin
-103.65%
This Stock
vs
-20.78%
Sector Avg
+398.9%
(Superior)
Debt to Equity
0.02
This Stock
vs
6.16
Sector Avg
-99.8%
(Less Debt)
Revenue Growth
57.6%
This Stock
vs
137.39%
Sector Avg
-58.1%
(Slower)
Current Ratio
4.44
This Stock
vs
3.36
Sector Avg
+32.0%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
ASMB
Assembly Biosciences, Inc.
|
NEUTRAL | $471.98M | - | -36.9% | -103.6% | $29.84 | |
|
BCYC
Bicycle Therapeutics plc
|
BEARISH | $482.11M | - | -34.6% | -% | $6.95 | |
|
AQST
Aquestive Therapeutics, Inc.
|
BEARISH | $490.45M | - | -% | -188.1% | $4.02 | |
|
ADCT
ADC Therapeutics SA
|
NEUTRAL | $447.2M | - | -% | -222.0% | $3.61 | |
|
ALT
Altimmune, Inc.
|
BEARISH | $438.31M | - | -50.6% | -% | $3.5 |
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
NONE
4 analysts
HC Wainwright & Co.
2025-12-22
Buy
Buy
Mizuho
2025-11-20
Outperform
Outperform
HC Wainwright & Co.
2025-10-14
Buy
Buy
JMP Securities
2025-09-24
Market Outperform
Guggenheim
2025-09-08
Buy
Buy
Past News Coverage
Recent headlines mentioning ASMB from our newsroom.
Newest → oldest
No matching news yet.